(Q37543912)

20 August 2017

1 reference

title

The epothilones: how pharmacology relates to clinical utility (English)

1 reference

20 August 2017

1 reference

Laura Boehnke Michaud

series ordinal

1

1 reference

20 August 2017

language of work or name

English

0 references

publication date

7 July 2009

1 reference

Annals of Pharmacotherapy

20 August 2017

published in

1 reference

20 August 2017

volume

43

1 reference

20 August 2017

issue

7

1 reference

20 August 2017

page(s)

1294-1309

1 reference

Paclitaxel in cancer therapy

20 August 2017

cites work

1 reference

THE DEVELOPMENT AND CLINICAL UTILITY OF THE TAXANE CLASS OF ANTIMICROTUBULE CHEMOTHERAPY AGENTS

21 January 2018

1 reference

Drug resistance reversal--are we getting closer?

21 January 2018

1 reference

Microtubule stabilizing agents: their molecular signaling consequences and the potential for enhancement by drug combination.

21 January 2018

1 reference

Microtubule targeting agents: basic mechanisms of multidrug resistance (MDR).

21 January 2018

1 reference

Epothilones: mechanism of action and biologic activity

21 January 2018

1 reference

Development of novel chemotherapeutic agents to evade the mechanisms of multidrug resistance (MDR).

21 January 2018

1 reference

The epothilones and related analogues-a review of their syntheses and anti-cancer activities

21 January 2018

1 reference

Desoxyepothilone B: an efficacious microtubule-targeted antitumor agent with a promising in vivo profile relative to epothilone B.

21 January 2018

1 reference

Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol(R)).

21 January 2018

1 reference

Recent developments in the chemical biology of epothilones

21 January 2018

1 reference

Desoxyepothilone B is curative against human tumor xenografts that are refractory to paclitaxel.

21 January 2018

1 reference

The synthesis, discovery, and development of a highly promising class of microtubule stabilization agents: curative effects of desoxyepothilones B and F against human tumor xenografts in nude mice

21 January 2018

1 reference

Targeting the microtubules in breast cancer beyond taxanes: the epothilones

21 January 2018

1 reference

Preclinical efficacy spectrum and pharmacokinetics of ixabepilone

21 January 2018

1 reference

Microtubule alterations and mutations induced by desoxyepothilone B: implications for drug-target interactions

21 January 2018

1 reference

A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells

21 January 2018

1 reference

Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization

21 January 2018

1 reference

Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo

21 January 2018

1 reference

Pharmacokinetics and pharmacodynamics of estramustine phosphate

21 January 2018

1 reference

Epothilones and the next generation of phase III trials for prostate cancer

21 January 2018

1 reference

Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer.

21 January 2018

1 reference

Pilot study of epothilone B analog (BMS-247550) and estramustine phosphate in patients with progressive metastatic prostate cancer following castration

21 January 2018

1 reference

Human mass balance study of the novel anticancer agent ixabepilone using accelerator mass spectrometry.

21 January 2018

1 reference

Efficacy and safety of ixabepilone, a novel epothilone analogue.

21 January 2018

1 reference

In vivo metabolism of epothilone B in tumor-bearing nude mice: identification of three new epothilone B metabolites by capillary high-pressure liquid chromatography/mass spectrometry/tandem mass spectrometry

21 January 2018

1 reference

Phase I dose-finding study of weekly single-agent patupilone in patients with advanced solid tumors

21 January 2018

1 reference

Potential radiation-sensitizing effect of semisynthetic epothilone B in human lung cancer cells

21 January 2018

1 reference

Patupilone acts as radiosensitizing agent in multidrug-resistant cancer cells in vitro and in vivo.

21 January 2018

1 reference

Improved cellular pharmacokinetics and pharmacodynamics underlie the wide anticancer activity of sagopilone

21 January 2018

1 reference

Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days.

21 January 2018

1 reference

Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas

21 January 2018

1 reference

Phase I clinical trial of BMS-247550, a derivative of epothilone B, using accelerated titration 2B design

21 January 2018

1 reference

Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors

21 January 2018

1 reference

Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer

21 January 2018

1 reference

Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment

21 January 2018

1 reference

Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111.

21 January 2018

1 reference

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

21 January 2018

1 reference

A phase II trial of the epothilone B analog, BMS-247550, in patients with previously treated advanced colorectal cancer

21 January 2018

1 reference

Evaluation of epothilone B analog in advanced soft tissue sarcoma: a phase II study of the phase II consortium.

21 January 2018

1 reference

Phase 2 trial of epothilone B analog BMS-247550 (ixabepilone) in advanced carcinoma of the urothelium (E3800): a trial of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

A multicentre phase II clinical experience with the novel aza-epothilone Ixabepilone (BMS247550) in patients with relapsed or refractory indolent non-Hodgkin lymphoma and mantle cell lymphoma

21 January 2018

1 reference

A phase I trial of gemcitabine in combination with patupilone in patients with advanced solid tumors

21 January 2018

1 reference

Total synthesis and antitumor activity of ZK-EPO: the first fully synthetic epothilone in clinical development.

21 January 2018

1 reference

Randomized trial of two or five computed tomography scans in the surveillance of patients with stage I nonseminomatous germ cell tumors of the testis: Medical Research Council Trial TE08, ISRCTN56475197--the National Cancer Research Institute Testis

21 January 2018

1 reference

Epothilones: a novel class of microtubule-stabilizing drugs for the treatment of cancer

21 January 2018

1 reference

A multi-center phase II study of BMS-247550 (Ixabepilone) by two schedules in patients with metastatic gastric adenocarcinoma previously treated with a taxane

21 January 2018

1 reference

Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer

21 January 2018

1 reference

Epothilons A and B: antifungal and cytotoxic compounds from Sorangium cellulosum (Myxobacteria). Production, physico-chemical and biological properties

21 January 2018

1 reference

12 April 2024

https://opencitations.net/index/api/v1/citations/10.7164/ANTIBIOTICS.49.560

Identifiers

DOI

10.1345/APH.1M005

1 reference

20 August 2017

1 reference